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Introduction
The urea cycle is the major pathway of nitrogen 
metabolism in the human body. Excess nitrogen, in 
the form of ammonia, is converted via this cycle to 
urea and excreted through the kidneys. In humans, 
the cycle entails five key enzymes, including 
carbamoyl-phosphate synthetase I (CPS1), ornithine 
transcarbamylase (OTC), argininosuccinate syn-
thetase, argininosuccinate lyase, and arginase; while 
an additional enzyme named N-acetylglutamate 
synthase provides CPS1 with its essential cofactor.1 
A defect in any of these six enzymatic pathways or 
the two associated transporters, namely citrin and 
ornithine translocase, causes urea cycle disorders.2 
Patients with complete deficiency of the affected 
enzyme present with significant hyperammonaemia 
in the neonatal period. It is a serious and often 
lethal condition or causes irreversible brain damage 
especially when the diagnosis or treatment is delayed 
or ineffective. On the other hand, patients with partial 
enzyme deficiencies or defective transporters can 
present later in life, from infancy to adulthood, and 
manifest whenever the urea cycle is overwhelmed by 
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homocitrullinuria syndrome is an autosomal 
recessive disorder caused by a defect in ornithine 
translocase. This condition leads to variable 
clinical presentations, including episodic 
hyperammonaemia, hepatic derangement, and 
chronic neurological manifestations. Fewer than 100 
affected patients have been reported worldwide. Here 
we report the first two cases in Hong Kong Chinese, 
who were compound heterozygous siblings for 
c.535C>T (p.Arg179*) and c.815C>T (p.Thr272Ile) 
in the SLC25A15 gene. When the mother refused 
prenatal diagnosis for the second pregnancy, urgent 
genetic testing provided the definitive diagnosis 
within 24 hours to enable specific treatment. 
Optimal management of these two patients relied on 
the concerted efforts of a multidisciplinary team and 
illustrates the importance of an expanded newborn 
screening service for early detection and treatment 
of inherited metabolic diseases.
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environmental triggers or stresses. These result in 
acute hyperammonaemic episodes.2
 Hyperornithinaemia-hyperammonaemia-
homocitrullinuria syndrome (HHH syndrome; 
MIM#238970) is an autosomal recessive disorder 
caused by a defect in ornithine translocase 
(SLC25A15 or ORNT1, MIM*603861). The disorder 
is exceedingly rare; with fewer than 100 patients 
having been reported worldwide, although its 
incidence in northern Saskatchewan in Canada 
was estimated to be 1 in 1500 (with a carrier rate 
of 1 in 19).3 The syndrome was first described by 
Shih et al4 in 1969 with a neurological phenotype 
entailing seizures and mental retardation. It was 
later found that the clinical presentations of HHH 
syndrome can be highly variable, and include spastic 
paraplegia, pyramidal and extrapyramidal signs, 
stroke-like episodes, hypotonia, seizures, ataxia, 
protein intolerance, failure to thrive, and hepatic 
failure.5-7 Liver biopsies typically reveal vacuolated 
hepatocytes distended with glycogen on light 
microscopy and bizarre-looking mitochondria on 
electronic microscopy.8 So far, no definite genotype-
phenotype correlation has been noted, with a high 
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高鳥胺酸血症—高氨血症—高瓜胺酸血綜合症（HHH）是一種常染
色體隱性遺傳疾病，因鳥胺酸轉位酶的缺陷而導致不同的臨床表現，
包括偶發性高氨血症、肝功能紊亂和慢性神經系統表現。受影響的患
者全球只有不足100個。本文報告具複合雜合性基因突變的兩名香港
華裔兄弟，他們的SLC25A15基因均出現c.535C>T（p.Arg179*）和
c.815C>T（p.Thr272Ile）兩種突變。由於母親第二次懷孕時拒絕作
產前診斷，當第二名兒子出生時須作緊急基因檢測，最終在24小時內
作出診斷並施以針對性治療。要治理這兩名患者有賴跨學科小組的共
同努力。本病例闡明了擴大新生兒篩查服務對於盡早診斷及醫治遺傳
代謝疾病尤為重要。
高鳥胺酸血症—高氨血症—高瓜胺酸血綜合
症：一種可治癒但須及早診斷的遺傳性肝臟病
degree of clinical heterogeneity even among patients 
harbouring the same genetic defect.9 However, 
patients with HHH syndrome can respond well to a 
low-protein diet with improvements in neurological 
symptoms and hepatic function, for which reason 
an accurate diagnosis is critical to management.5,10 
For the first time in Hong Kong, here we describe 
HHH syndrome in a pair of siblings and their clinical, 
biochemical, and molecular profiles, with a view 
to facilitate understanding of this disorder in our 
FIG.  The amino acid profile of the proband on different occasions
Black bar = pre-treatment at diagnosis; white bar = pre-meal sample; shaded bar = 
3 hours post-meal sample. Levels of selected amino acids at diagnosis: glutamine 723 
(reference range, 333-809) μmol/L, ornithine 503 (20-136) μmol/L, lysine 449 (60-
270) μmol/L, and methionine 49 (13-43) μmol/L
locality. The diagnosis of this family also revealed a 
possible founder mutation in ethnic Chinese.
Case report
The patient was an ethnic Han Chinese boy, born 
healthy to a non-consanguineous couple and fed on 
both human and formula milk in 2007. He presented 
with neonatal jaundice with serum bilirubin up to 338 
μmol/L (diazo method) or 295 μmol/L (photometric 
method) on day 5, which dropped to 179 μmol/L 
(photometric method) on day 6 after phototherapy. 
He was then discharged without further blood 
taking, since otherwise he was clinically well. 
However, 1 month later he presented with persistent 
jaundice and a liver palpable 2 cm below the costal 
margin but no clinical splenomegaly. The total 
bilirubin was 99 μmol/L with a direct bilirubin of 27 
(reference range [RR], 1-5) μmol/L and an alkaline 
phosphatase (ALP) of 529 (RR, 82-383) U/L. His 
γ-glutamyltransferase (GGT) ranged from 345 to 
388 (reference level, <220) U/L but the alanine 
transaminase (ALT) was normal at 32 to 35 (RR, 
4-35) U/L. While his bilirubin and GGT levels 
gradually normalised at 2 months, even at 12 months 
the ALT remained elevated at 311 U/L and the ALP 
was 418 U/L (RR, 104-345 U/L). A deranged clotting 
profile with a prothrombin time of 20.5 (RR, 10.4-
12.6; international normalised ratio, 2.0) seconds, an 
activated partial thromboplastin time of 36.3 (RR, 
26.4-35.3) seconds, and a serum bile acid level of 
10.8 (reference level, <7) μmol/L were noted. At this 
juncture, his liver remained palpable, 1 cm below 
the costal margin. In addition, he was noted to have 
alpha thalassaemia trait.
 At the age of 11 months, gas chromatography–
mass spectrometry of urine detected significant 
hyperexcretion of uracil and moderately excessive 
excretion of orotic acid, while he was taking an 
unrestricted protein diet (approximately 3 g/kg/day). 
He also had homocitrullinuria of up to 71 (reference 
level, <9) μmol/mmol creatinine, which was also 
demonstrated by liquid chromatography–tandem 
mass spectrometry. Plasma amino acids analysis by 
high-performance liquid chromatography detected 
excessive alanine, arginine, ornithine, and methionine 
concentrations, postprandially (Figure). At the age 
of 12 months, the blood ammonia was elevated at 
132 (RR, 16-60) μmol/L, the simultaneous blood 
glucose was 3.8 mmol/L, and the lactate was 2.5 
(RR, 0.5-2.2) mmol/L. The biochemical picture was 
suggestive of urea cycle dysfunction. Interestingly, 
at that juncture he was clinically well and had no 
vomiting or encephalopathy. His blood ammonia 
decreased to 59 μmol/L on rechecking after 24 
hours just before institution of protein restriction 
(0.9 g/kg/day); over the next 14 days it fluctuated 
between 43 and 84 μmol/L.
 Mutational analysis was performed by 
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polymerase chain reaction and Sanger sequencing 
with genomic DNA. While no mutation was noted 
in the OTC gene, the patient was shown to be 
heterozygous for two different mutations, c.535C>T 
(p.Arg179*) and c.815C>T (p.Thr272Ile), in the 
SLC25A15 gene. The latter missense mutation was 
not found in 100 Chinese control chromosomes 
tested. Compound heterozygosity was confirmed by 
analysing the parental DNA. 
 The patient’s liver became impalpable 1 month 
after therapy. Normalisation of the serum ALT level 
was noted 1 month after treatment, although plasma 
ornithine and urine orotic acid levels remained 
elevated. Coagulation factor VII and X levels were 
normal during convalescence. At the age of 6 years, 
the boy had no acute encephalopathy or pyramidal 
signs, but did exhibit mild clumsiness and subtle gait 
ataxia (only evident on tandem walking).
 The mother became pregnant 1 year later in 
2009, when the proband was 2 years old. In view of 
the family history of HHH syndrome, counselling was 
provided by the obstetrician early during gestation, yet 
the parents opted not to obtain a prenatal diagnosis. 
Prior arrangement was then made with the chemical 
pathologist to have a semi-urgent molecular diagnosis 
to facilitate therapy for the neonate if necessary. 
This younger brother was immediately started on a 
low protein (≤1.2 g/kg/day) diet, which consisted of 
breastfeeding and a zero-protein formula after delivery. 
Aged 12 hours, the postprandial blood ammonia was 
68 μmol/L (reference level, <100 μmol/L) and blood 
for molecular genetics was sampled simultaneously. 
The boy only had physiological jaundice and no 
other signs, but was also soon confirmed to have a 
compound heterozygous form of the two familial 
mutations about which the paediatrician was notified 
within 24 hours of blood sampling. In view of the 
prompt definitive diagnosis, protein restriction was 
continued with confidence. His ammonia peaked 
at 111 μmol/L and then normalised, whilst his 
ALT level remained normal in the neonatal period. 
His coagulation factors VII and X levels were also 
normal. The boy did not have any episodes of acute 
encephalopathy and developed normally when seen 
for follow-up at the age of 3 years.
Discussion
When arginase cleaves arginine in the last step of 
the urea cycle to produce urea and ornithine, the 
ornithine translocase enzyme transports cytosolic 
ornithine back into the mitochondria for subsequent 
urea cycles in exchange of mitochondrial citrulline.11 
The gene SLC25A15 was cloned in 1999 and found 
to account for the HHH syndrome,12 and molecular 
modelling was reported early in 2012.13 A founder 
mutation p.Phe188del was reported in French-
Canadian patients,12 and in Japanese patients the 
p.Arg179* mutation was also noted to be frequent.14,15
 The nonsense mutation p.Arg179* variant is 
predicted to cause premature termination of the 
protein. Although common in Japan,14 it was also 
reported in other ethnic groups.15 The missense 
mutation p.Thr272Ile was reported in 2009 by 
Tessa et al15 in one Taiwanese patient, with recently 
published functional proof of its pathogenicity. 
However, this missense mutation has never been 
reported in other ethnic groups. We therefore 
postulate that it could be a common mutation, 
possibly having an ancestral founder gene effect in 
ethnic Chinese. If this is confirmed in more patients 
of Chinese ethnicity, it may aid prioritising workflow 
for the genetic testing of individuals suspected to 
have HHH syndrome. In which case, they could 
undergo more focused molecular investigation 
instead of whole gene sequencing. Consequently, a 
more rapid diagnosis could enable more prompt and 
appropriate treatment.
 To the best of our knowledge, these were 
the first two cases of HHH syndrome reported in 
Hong Kong. The proband’s metabolic profile in 
early infancy was particularly illustrative of the 
natural course of the associated hepatic disease. 
The untreated first child had pronounced neonatal 
jaundice which responded to phototherapy and soon 
evolved into mild transient hyperbilirubinaemia 
with an accompanying elevation in serum ALP 
but not ALT levels in early infancy. Subsequently, 
despite resolution of jaundice, he showed moderate 
hepatocellular derangement and dysfunction with 
a coagulopathy and hyperammonaemia, which 
responded to protein restriction. The younger 
brother had no serum ALT level elevation while the 
ammonia level was only mildly raised in the first week 
of life, at which time he was proactively commenced 
on protein restriction. These two cases demonstrate 
that metabolic profiling, including the ammonia 
level, should be included in the initial workup for any 
infant with unexplained prolonged liver dysfunction 
and may provide a clue to a possible underlying 
defect in the urea cycle. The HHH syndrome is rare, 
yet a readily treatable cause to consider in Chinese 
patients with unusual plasma amino acid patterns. In 
addition, modern medical technologies (eg tandem 
mass spectrometry) allow multiplex screening of 
classical inherited metabolic disorders that can 
detect HHH syndrome using hyperornithinaemia as 
the disease marker.16 The successful diagnosis and 
management of these siblings entailed a concerted 
effort and collaboration of a multidisciplinary team. 
Notably, the diagnosis of rare diseases is often 
difficult, and the importance of having an integrated 
pathology service is crucial.
 Prenatal diagnosis for the younger brother was 
possible but declined by the parents, making timely 
intervention of the chemical pathology laboratory 
even more critical for establishing or excluding the 
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diagnosis in the neonate. In this clinical setting, 
a rapid and definitive diagnosis (within 24 hours) 
provided by genetic testing was important as a 
mildly elevated ammonia level in an asymptomatic 
newborn may be hard to interpret. It allowed the 
clinicians to counsel the parents accordingly on the 
need for lifelong protein restriction to minimise 
the chance of decompensation. Although late-
onset long-term neurological sequelae may not be 
preventable,9 it is prudent to keep the two children 
metabolically stable as far as possible, to mitigate 
brain damage from decompensation. 
 In conclusion, HHH syndrome, although very 
rare, is an inborn error of metabolism that can occur 
in the Chinese and is readily detectable by tandem 
mass spectrometry.17 If this technique could be 
introduced to support a local newborn screening 
programme, many more possibly treatable metabolic 
disorders may be picked up.
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